Cite
HARVARD Citation
Takeuchi, T. et al. (2019). Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. Annals of the rheumatic diseases. 78 (7), pp. 899-. [Online].